ReviewDrugs2021
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Pooled it
- The intervention effect of psychological care combined with ondansetron, dexamethasone, and promethazine hydrochloride on chemotherapy in breast cancer surgical patients.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Trial
- Trial
- Palonosetron-loaded binary ethosome-incorporated transdermal gel: Formulation optimization, in vitro/in vivo evaluation, and therapeutic efficacy in chemotherapy-induced nausea and vomiting.International journal of pharmaceutics: X · 2026Article
- Efficacy of NEPA for prevention of chemotherapy induced nausea and vomiting in head and neck cancer patients receiving cisplatin-based chemotherapy.European journal of clinical pharmacology · 2026Article
- Article
- Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis.Blood science (Baltimore, Md.) · 2026Article
- Palonosetron, a 5-HT3 Receptor Antagonist, Induces G1 Cell Cycle Arrest and Autophagy in Gastric Cancer Cells.International journal of molecular sciences · 2025Article
- Deciphering key chemotherapeutic drug targets within tyrosine metabolism for breast cancer and advancing a wide-ranging diagnostic strategy.Discover oncology · 2025Article
- Netupitant Exhibits Potent Activity onACS infectious diseases · 2025Article
- Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting.Frontiers of medicine · 2025Review
- The safety and efficacy of NEPA in preventing postoperative nausea and vomiting after general anesthesia during gastrointestinal cancer surgery: a single-center retrospective study.Translational cancer research · 2025Article
- Comparative efficacy of prophylactic protocols in reducing perioperative nausea and vomiting during video-assisted thoracoscopic radical resection of lung cancer.Scientific reports · 2024Article
- Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.International journal of molecular sciences · 2024Article
- Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database.Frontiers in pharmacology · 2024Article
- Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011-2023.Molecules (Basel, Switzerland) · 2023Review
- The transit of oral premedication beyond the stomach in patients undergoing laparoscopic sleeve gastrectomy: a retrospective observational multicentre study.BMC surgery · 2023Observational
- Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective.Advances in therapy · 2023Review
- Article
- Network pharmacology and experimental verification-based strategy to explore the underlying mechanism of Liu Jun An Wei formula in the treatment of gastrointestinal reactions caused by chemotherapy for colorectal cancer.Frontiers in pharmacology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Netupitant/palonosetron (NEPA; Akynzeo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.